Abstract
Caspofungin represents a useful option for the treatment of invasive aspergillosis. It was approved by the Food and Drug Administration on the basis of one noncomparative trial in < 100 patients whose disease was refractory to other therapies. This agent has not been studied as a first-line therapy for invasive aspergillosis, nor has it been extensively studied in invasive fungal infections caused by other organisms. At present, caspofungin's use should be restricted to single-agent therapy of documented invasive aspergillosis in patients who are intolerant of or whose disease is refractory to amphotericin B and/or itraconazole therapy. Its lower cost and probable superior tolerability compared with liposomal amphotericin B make Caspofungin an intriguing candidate for first-line therapy when more data are available.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
